Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study ID
NCT06733987
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a single-centre, observational, prospective and exploratory study, which involves the use of human tissues from patients affected by Relapsed/Refractory classic Hodgkin Lymphoma treated with pembrolizumab at the Departmental Diagnosis and Therapy program for chronic lymphoproliferative syndromes of the IRCCS AOU of Bologna. Peripheral blood samples will be used for the study and will be taken: * before starting treatment with pembrolizumab. * undergoing therapy with pembrolizumab (cycle 2 (C2), C3, C4, C8, C12).

Key Dates

First listed
Dec 13, 2024
Start date
Aug 1, 2024
Status verified
Dec 2024
Primary completion
Feb 1, 2027
Completion
Feb 1, 2027

Study Design

Enrollment
40 participants (estimated)

Primary Outcome Measure

correlation between immunological profile of SIP and response to pembrolizumab [ Time Frame: At the end of Cycle 2 (each cycle is 21 days) ]

Central Contacts

Related Studies